Use of Medicines
Medicines aim to cure diseases, or at least relieve symptoms, to enable longer, healthier and more productive lives. Access to appropriate medicines, used sustainably, has substantial benefits for community health and related economic indicators.
Individual, Health System, and Societal Impacts of Anti-seizure Medicine Use During Pregnancy
23 January 2024
Explore the implications of in utero exposure to anti-seizure medications (ASMs), the heightened risks of developmental problems and physical disabilities. The economic impact associated with conditions like epilepsy, stressing the urgent need for detailed risk profiles and data collection to guide interventions and reduce the societal costs linked to ASM use during pregnancy.
The Dynamics of Drug Shortages
9 January 2024
Drug shortages are an industry-wide problem. Numerous factors may be considered as contributing to drug shortages across the globe. In this report, we discuss the global issue of drug shortages, summarise the main reasons for shortages as presented in the literature and our quantitative analysis. Finally, we provide recommendations for policy makers.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
16 June 2021
Our new paper explores the evidence currently being used to allocate budgets between public sector activities in the UK and its limitations. We argue that there…
Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System
31 March 2021
In the contentious debate around US drug prices, less well understood is: if the price of a drug is a fair, value-based, price, how we assess…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those…
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for…
Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
1 February 2021
Using medicines in combination can deliver better outcomes for patients across different tumour types and disease stages. Yet many HTA agencies do not find that the…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
As the world is figuring out how to deal with COVID-19, it is worth taking stock of the broader value that existing vaccines bring to societies…